KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas

Riley E. Alexander, Antonio Lopez-Beltran, Rodolfo Montironi, Gregory T. MacLennan, Kristin M. Post, Sarah A. Bilbo, Timothy D. Jones, Wenbin Huang, Qiu Rao, Joyashree D. Sen, Kari Meehan, Anita Cornwell, Leticia Miravalle, Liang Cheng

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Aims: To determine whether KRAS mutations occur in primary bladder adenocarcinoma. Methods and results: Twenty-six cases of primary urinary bladder adenocarcinoma were analysed. DNA was extracted from formalin-fixed, paraffin-embedded tissue and amplified with shifted termination assay technology, which recognizes wild-type or mutant target sequences and selectively extends detection primers with labelled nucleotides. A mutation in KRAS was found in three (11.5%) of 26 primary bladder adenocarcinomas. Two of these three cases exhibited a G13D mutation, whereas the remaining case contained a mutation in G12V. None of the ten cases of urothelial carcinoma with glandular differentiation displayed KRAS mutation. Colonic adenocarcinoma contained a KRAS mutation in 18 (33%) of 55 cases. There was no distinct difference with regard to grade, stage or outcome according to the limited clinicopathological data available. However, the two youngest patients, aged 32 and 39years, in our study group, with a mean population age of 61years, were found to have mutations in KRAS. Conclusions: KRAS mutations are present in a small subset of primary urinary bladder adenocarcinomas. Future clinical trials for treatment of bladder adenocarcinoma, employing targeted therapies similar to those used for treatment of colon cancer, may also benefit from the predictive implications of KRAS mutational testing.

Original languageEnglish
Pages (from-to)1036-1042
Number of pages7
JournalHistopathology
Volume61
Issue number6
DOIs
StatePublished - Dec 2012

Fingerprint

Urinary Bladder
Adenocarcinoma
Mutation
Paraffin
Colonic Neoplasms
Formaldehyde
Therapeutics
Nucleotides
Clinical Trials
Technology
Carcinoma
DNA
Population

Keywords

  • Adenocarcinoma
  • Carcinogenesis
  • Differential diagnosis
  • KRAS mutation
  • Targeted therapy
  • Urinary bladder
  • Urothelial carcinoma with glandular differentiation

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine

Cite this

Alexander, R. E., Lopez-Beltran, A., Montironi, R., MacLennan, G. T., Post, K. M., Bilbo, S. A., ... Cheng, L. (2012). KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas. Histopathology, 61(6), 1036-1042. https://doi.org/10.1111/j.1365-2559.2012.04309.x

KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas. / Alexander, Riley E.; Lopez-Beltran, Antonio; Montironi, Rodolfo; MacLennan, Gregory T.; Post, Kristin M.; Bilbo, Sarah A.; Jones, Timothy D.; Huang, Wenbin; Rao, Qiu; Sen, Joyashree D.; Meehan, Kari; Cornwell, Anita; Miravalle, Leticia; Cheng, Liang.

In: Histopathology, Vol. 61, No. 6, 12.2012, p. 1036-1042.

Research output: Contribution to journalArticle

Alexander, RE, Lopez-Beltran, A, Montironi, R, MacLennan, GT, Post, KM, Bilbo, SA, Jones, TD, Huang, W, Rao, Q, Sen, JD, Meehan, K, Cornwell, A, Miravalle, L & Cheng, L 2012, 'KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas', Histopathology, vol. 61, no. 6, pp. 1036-1042. https://doi.org/10.1111/j.1365-2559.2012.04309.x
Alexander RE, Lopez-Beltran A, Montironi R, MacLennan GT, Post KM, Bilbo SA et al. KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas. Histopathology. 2012 Dec;61(6):1036-1042. https://doi.org/10.1111/j.1365-2559.2012.04309.x
Alexander, Riley E. ; Lopez-Beltran, Antonio ; Montironi, Rodolfo ; MacLennan, Gregory T. ; Post, Kristin M. ; Bilbo, Sarah A. ; Jones, Timothy D. ; Huang, Wenbin ; Rao, Qiu ; Sen, Joyashree D. ; Meehan, Kari ; Cornwell, Anita ; Miravalle, Leticia ; Cheng, Liang. / KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas. In: Histopathology. 2012 ; Vol. 61, No. 6. pp. 1036-1042.
@article{3758ea8b1fa446709ad92334aa10c6ca,
title = "KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas",
abstract = "Aims: To determine whether KRAS mutations occur in primary bladder adenocarcinoma. Methods and results: Twenty-six cases of primary urinary bladder adenocarcinoma were analysed. DNA was extracted from formalin-fixed, paraffin-embedded tissue and amplified with shifted termination assay technology, which recognizes wild-type or mutant target sequences and selectively extends detection primers with labelled nucleotides. A mutation in KRAS was found in three (11.5{\%}) of 26 primary bladder adenocarcinomas. Two of these three cases exhibited a G13D mutation, whereas the remaining case contained a mutation in G12V. None of the ten cases of urothelial carcinoma with glandular differentiation displayed KRAS mutation. Colonic adenocarcinoma contained a KRAS mutation in 18 (33{\%}) of 55 cases. There was no distinct difference with regard to grade, stage or outcome according to the limited clinicopathological data available. However, the two youngest patients, aged 32 and 39years, in our study group, with a mean population age of 61years, were found to have mutations in KRAS. Conclusions: KRAS mutations are present in a small subset of primary urinary bladder adenocarcinomas. Future clinical trials for treatment of bladder adenocarcinoma, employing targeted therapies similar to those used for treatment of colon cancer, may also benefit from the predictive implications of KRAS mutational testing.",
keywords = "Adenocarcinoma, Carcinogenesis, Differential diagnosis, KRAS mutation, Targeted therapy, Urinary bladder, Urothelial carcinoma with glandular differentiation",
author = "Alexander, {Riley E.} and Antonio Lopez-Beltran and Rodolfo Montironi and MacLennan, {Gregory T.} and Post, {Kristin M.} and Bilbo, {Sarah A.} and Jones, {Timothy D.} and Wenbin Huang and Qiu Rao and Sen, {Joyashree D.} and Kari Meehan and Anita Cornwell and Leticia Miravalle and Liang Cheng",
year = "2012",
month = "12",
doi = "10.1111/j.1365-2559.2012.04309.x",
language = "English",
volume = "61",
pages = "1036--1042",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas

AU - Alexander, Riley E.

AU - Lopez-Beltran, Antonio

AU - Montironi, Rodolfo

AU - MacLennan, Gregory T.

AU - Post, Kristin M.

AU - Bilbo, Sarah A.

AU - Jones, Timothy D.

AU - Huang, Wenbin

AU - Rao, Qiu

AU - Sen, Joyashree D.

AU - Meehan, Kari

AU - Cornwell, Anita

AU - Miravalle, Leticia

AU - Cheng, Liang

PY - 2012/12

Y1 - 2012/12

N2 - Aims: To determine whether KRAS mutations occur in primary bladder adenocarcinoma. Methods and results: Twenty-six cases of primary urinary bladder adenocarcinoma were analysed. DNA was extracted from formalin-fixed, paraffin-embedded tissue and amplified with shifted termination assay technology, which recognizes wild-type or mutant target sequences and selectively extends detection primers with labelled nucleotides. A mutation in KRAS was found in three (11.5%) of 26 primary bladder adenocarcinomas. Two of these three cases exhibited a G13D mutation, whereas the remaining case contained a mutation in G12V. None of the ten cases of urothelial carcinoma with glandular differentiation displayed KRAS mutation. Colonic adenocarcinoma contained a KRAS mutation in 18 (33%) of 55 cases. There was no distinct difference with regard to grade, stage or outcome according to the limited clinicopathological data available. However, the two youngest patients, aged 32 and 39years, in our study group, with a mean population age of 61years, were found to have mutations in KRAS. Conclusions: KRAS mutations are present in a small subset of primary urinary bladder adenocarcinomas. Future clinical trials for treatment of bladder adenocarcinoma, employing targeted therapies similar to those used for treatment of colon cancer, may also benefit from the predictive implications of KRAS mutational testing.

AB - Aims: To determine whether KRAS mutations occur in primary bladder adenocarcinoma. Methods and results: Twenty-six cases of primary urinary bladder adenocarcinoma were analysed. DNA was extracted from formalin-fixed, paraffin-embedded tissue and amplified with shifted termination assay technology, which recognizes wild-type or mutant target sequences and selectively extends detection primers with labelled nucleotides. A mutation in KRAS was found in three (11.5%) of 26 primary bladder adenocarcinomas. Two of these three cases exhibited a G13D mutation, whereas the remaining case contained a mutation in G12V. None of the ten cases of urothelial carcinoma with glandular differentiation displayed KRAS mutation. Colonic adenocarcinoma contained a KRAS mutation in 18 (33%) of 55 cases. There was no distinct difference with regard to grade, stage or outcome according to the limited clinicopathological data available. However, the two youngest patients, aged 32 and 39years, in our study group, with a mean population age of 61years, were found to have mutations in KRAS. Conclusions: KRAS mutations are present in a small subset of primary urinary bladder adenocarcinomas. Future clinical trials for treatment of bladder adenocarcinoma, employing targeted therapies similar to those used for treatment of colon cancer, may also benefit from the predictive implications of KRAS mutational testing.

KW - Adenocarcinoma

KW - Carcinogenesis

KW - Differential diagnosis

KW - KRAS mutation

KW - Targeted therapy

KW - Urinary bladder

KW - Urothelial carcinoma with glandular differentiation

UR - http://www.scopus.com/inward/record.url?scp=84870362446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870362446&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2559.2012.04309.x

DO - 10.1111/j.1365-2559.2012.04309.x

M3 - Article

C2 - 22804747

AN - SCOPUS:84870362446

VL - 61

SP - 1036

EP - 1042

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 6

ER -